- Home
- CHMI vs SNTI Comparison
CHMI vs SNTI Comparison
Compare CHMI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- SNTI
- Stock Information
- Founded
- CHMI 2012
- SNTI 2016
- Country
- CHMI United States
- SNTI United States
- Employees
- CHMI N/A
- SNTI N/A
- Industry
- CHMI Real Estate Investment Trusts
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- CHMI Real Estate
- SNTI Health Care
- Exchange
- CHMI Nasdaq
- SNTI Nasdaq
- Market Cap
- CHMI 89.2M
- SNTI 85.3M
- IPO Year
- CHMI 2013
- SNTI N/A
- Fundamental
- Price
- CHMI $2.79
- SNTI $2.21
- Analyst Decision
- CHMI Hold
- SNTI Strong Buy
- Analyst Count
- CHMI 2
- SNTI 2
- Target Price
- CHMI N/A
- SNTI $8.50
- AVG Volume (30 Days)
- CHMI 338.7K
- SNTI 380.4K
- Earning Date
- CHMI 08-07-2025
- SNTI 08-12-2025
- Dividend Yield
- CHMI 21.50%
- SNTI N/A
- EPS Growth
- CHMI N/A
- SNTI N/A
- EPS
- CHMI N/A
- SNTI N/A
- Revenue
- CHMI $27,506,000.00
- SNTI N/A
- Revenue This Year
- CHMI N/A
- SNTI N/A
- Revenue Next Year
- CHMI $54.92
- SNTI $150.00
- P/E Ratio
- CHMI N/A
- SNTI N/A
- Revenue Growth
- CHMI 19.59
- SNTI N/A
- 52 Week Low
- CHMI $2.34
- SNTI $1.52
- 52 Week High
- CHMI $3.95
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- CHMI 45.14
- SNTI 43.19
- Support Level
- CHMI $2.73
- SNTI $2.10
- Resistance Level
- CHMI $2.82
- SNTI $2.43
- Average True Range (ATR)
- CHMI 0.08
- SNTI 0.18
- MACD
- CHMI -0.01
- SNTI 0.05
- Stochastic Oscillator
- CHMI 40.00
- SNTI 79.25
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.